The April 2017 edition of Pharmafocus is available to read online now!
From industry reaction to NICE’s new regulatory guidelines to the rising threat of counterfeit medicine, you can read all the latest developments and insight into the pharma industry in our newest issue.
Following a contentious consultation period, NICE has revealed new guidelines on its appraisal process for Highly Specialised Technologies, as well as a new 'Fast-track' pathway, but many industry figures aren't happy with the changes, calling them a step backwards rather than forwards; we have the full story, as well as comment from Alexion and an in-depth interview with the ABPI's Value and Access Director Paul Catchpole discussing his thoughts on the new accelerated approval pathway.
Drug counterfeiting is on the rise, growing to become a $200 billion market, posing a risk to countless unwitting patients across the world; Ben Hargreaves investigates the threat it poses and what the industry is doing to fight back in our first feature.
In our second feature, Matt Fellows explores the potentially wide-reaching effects of Regulation 536/2014, a new set of EU-wide rules which promise to streamline clinical trial processes across all Member States. But where does this leave Britain post-Brexit?
With Rare Disease Day rounding out the end of February, Pharmafocus goes behind the event in our third feature to explore its history and speak to some of those who are on the frontlines, working to increase visibility of those suffering from rare diseases and do more to increase access to treatment.
Think tank Reform delves into the world of Big Data to explore how the growing phenomenon can be harnessed to supercharge research, development and more in the pharma industry, and we scrutinise Chancellor Philip Hammond's recent budget - one that promises to place life sciences at the forefront of the UK economy.